The blood-brain barrier and nasal drug delivery to the central nervous system

American Journal of Rhinology and Allergy

Volumn 29, Issue 2, 2015, Pages 124-127

  Miyake, Marcel Menon ^a   Bleier, Benjamin S ^b  

^a Irmandade da Santa Casa de Misericórdia de Sã o Paulo ^*  (Brazil)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; BACLOFEN; CYTARABINE; DRUG CARRIER; HYDROCORTISONE; LIPOSOME; METHOTREXATE;

ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CHEMICAL STRUCTURE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG POTENCY; DRUG TARGETING; HUMAN; NON INVASIVE PROCEDURE; NONHUMAN; NOSE MUCOSA; OLFACTORY EPITHELIUM; OLFACTORY SYSTEM; SKULL SURGERY; SUBARACHNOID SPACE; SURGICAL TECHNIQUE; TRANSCYTOSIS; ANIMAL; BRAIN DISEASES; DRUG EFFECTS; ENDOSCOPY; INTRANASAL DRUG ADMINISTRATION; PHYSIOLOGY; PLASTIC SURGERY; PROCEDURES; SKULL BASE; SURGERY; SURGICAL FLAPS; UTILIZATION;

ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN DISEASES; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; ENDOSCOPY; HUMANS; NASAL MUCOSA; OLFACTORY PATHWAYS; RECONSTRUCTIVE SURGICAL PROCEDURES; SKULL BASE; SUBARACHNOID SPACE; SURGICAL FLAPS;

EID: 84925725578     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2015.29.4149     Document Type: Article

References (70)

1. Shoichet MS, and Winn SR Cell delivery to the central nervous system. Adv Drug Deliv Rev 42: 81-102, 2000.
2. Ngwuluka N, Pillay V, Du Toit LC, et al. Levodopa delivery systems: Advancements in delivery of the gold standard. Expert Opin Drug Deliv 7: 203-224, 2010.
3. Pathan SA, Iqbal Z, and Zaidi SM CNS drug delivery systems: Novel approaches. Recent Pat Drug Deliv Formul 3: 71-89, 2009.
4. Ricci M, Blasi P, Giovagnoli S, and Rossi C. Delivering drugs to the central nervous system: A medicinal chemistry or a pharmaceutical technology issue? Curr Med Chem 13: 1757-1775, 2006.
5. Patel MM, Goyal BR, Bhadada S V, et al. Getting into the brain: Approaches to enhance brain drug delivery. CNS Drugs 23: 35-58, 2009.
6. Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 45: 977-986, 1988.
7. Pardridge WM Blood-brain barrier delivery. Drug Discov Today 12: 54-61, 2007.
8. Jogani V, Jinturkar K, Vyas T, and Misra A. Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul 2: 25-40, 2008.
9. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, et al. Getting into the brain: Approaches to enhance brain drug delivery. CNS Drugs 23: 35-58, 2009.
10. Merkus P, Guchelaar HJ, Bosch DA, and Merkus FW. Direct access of drugs to the human brain after intranasal drug administration? Neurology 60: 1669-1671, 2003.
11. Chen Y, Dalwadi G, and Benson HA Drug delivery across the blood-brain barrier. Curr Drug Deliv 1: 361-76, 2004.
12. Dhuria SV, Hanson LR, and Frey WH 2nd. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 99: 1654-1673, 2010.
13. Frey II WH. Bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Dev Deliv 2: 46-49, 2002.
14. Dhanda DS, Frey II WH, Leopold D, and Kompella UB. Approaches for drug deposition in the human olfactory epithelium. Sect Title Pharm 5: 64-72, 2005.
15. Groothuis DR, and Levy RM The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol 3: 387-400, 1997.
16. Pardridge WM, Eisenberg J, and Yang J. Human blood-brain barrier transferrin receptor. Metabolism 36: 892-895, 1987.
17. Pardridge WM, Kang YS, Buciak JL, and Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12: 807-816, 1995.
18. Schlosshauer B, and Steuer H. Comparative anatomy, physiology and in vitro models of the blood-brain and blood-retina barrier. Curr Med Chem 2: 175-186, 2002.
19. Bodor N, and Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 36: 229-254, 1999.
20. Butt AM, Jones HC, and Abbott NJ Electrical resistance across the blood-brain barrier in anaesthetized rats: A developmental study. J Physiol 429: 47-62, 1990.
21. Kacem K, Lacombe P, Seylaz J, and Bonvento G. Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: A confocal microscopy study. Glia 23: 1-10, 1998.
22. Begley DJ The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48: 136-146, 1996.
23. Ghersi-Egea JF, and Strazielle N. Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus. Microsc Res Tech 52: 83-88, 2001.
24. Lee G, Dallas S, Hong M, and Bendayan R. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 53: 569-596, 2001.
25. Fromm MF P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38: 69-74, 2000.
26. Mizuno N, Niwa T, Yotsumoto Y, and Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55: 425-461, 2003.
27. Pardridge WM William Pardridge discusses the lack of BBB research. Interview by Rebecca N. Lawrence. Drug Discov Today 7: 223-226, 2002.
28. Cosolo WC, Martinello P, Louis WJ, and Christophidis N. Blood-brain barrier disruption using mannitol: Time course and electron microscopy studies. Am J Physiol 256(2 pt. 2): R443-R447, 1989.
29. Salahuddin TS, Johansson BB, Kalimo H, and Olsson Y. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol 77: 5-13, 1988.
30. Lossinsky AS, Vorbrodt AW, and Wisniewski HM Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier. J Neurocytol 24: 795-806, 1995.
31. Calias P, Banks WA, Begley D, et al. Intrathecal delivery of protein therapeutics to the brain: A critical reassessment. Pharmacol Ther 144: 114-122, 2014.
32. Smith HS, Deer TR, Staats PS, et al. Intrathecal drug delivery. Pain Physician 11(2 suppl.): S89-S104, 2008.
33. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39: 1267-1284, 2004.
34. Siegal T. Leptomeningeal metastases: Rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 38: 151-157, 1998.
35. Pullen J, Boyett J, Shuster J, et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poorrisk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 11: 839-849, 1993.
36. Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39: 125-133; discussion 133-134, 1996.
37. Krewson CE, Klarman ML, and Saltzman WM Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res 680: 196-206, 1995.
38. Bleier BS, Kohman RE, Feldman RE, et al. Permeabilization of the blood-brain barrier via mucosal engrafting: Implications for drug delivery to the brain. PLoS One 8: 1-7, 2013.
39. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595, 2003.
40. Hanson LR, and Frey WH Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9(suppl. 3): S5, 2008.
41. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 87: 187-198, 2003.
42. Draghia R, Caillaud C, Manicom R, et al. Gene delivery into the central nervous system by nasal instillation in rats. Gene Ther 2: 418-423, 1995.
43. Liu XF, Fawcett JR, Thorne RG, et al. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 187: 91-97, 2001.
44. Vyas TK, Shahiwala A, Marathe S, and Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv 2: 165-175, 2005.
45. Dorman DC, Brenneman KA, McElveen AM, et al. Olfactory transport: A direct route of delivery of inhaled manganese phosphate to the rat brain. J Toxicol Environ Health A 65: 1493-1511, 2002.
46. Derad I, Willeke K, Pietrowsky R, et al. Intranasal angiotensin II directly influences central nervous regulation of blood pressure. Am J Hypertens 11(8 pt. 1): 971-977, 1998.
47. Chow HS, Chen Z, and Matsuura GT Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 88: 754-758, 1999.
48. Wang Y, Aun R, and Tse FL Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos 19: 571-575, 1998.
49. Eriksson C, Bergman U, Franzén A, et al. Transfer of some carboxylic acids in the olfactory system following intranasal administration. J Drug Target 7: 131-142, 1999.
50. Chow HH, Anavy N, and Villalobos A. Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J Pharm Sci 90: 1729-1735, 2001.
51. Westin UE, Boström E, Gråsjo J, et al. Direct nose-to-brain transfer of morphine after nasal administration to rats. Pharm Res 23: 565-572, 2006.
52. Westin U, Piras E, Jansson B, et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 24: 565-573, 2005.
53. Wang X, He H, Leng W, and Tang X. Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method. Int J Pharm 317: 40-46, 2006.
54. Banks WA, Morley JE, Niehoff ML, and Mattern C. Delivery of testosterone to the brain by intranasal administration: Comparison to intravenous testosterone. J Drug Target 17: 91-97, 2009.
55. de Souza Silva MA, Mattern C, Topic B, et al. Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by intranasal administration of testosterone. Eur Neuropsychopharmacol 19: 53-63, 2009.
56. Dahlin M, Bergman U, Jansson B, et al. Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res 17: 737-742, 2000.
57. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: A transnasal approach to the human brain. Nat Neurosci 5: 514-516, 2002.
58. van den Berg MP, Verhoef JC, Romeijn SG, and Merkus FW. Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm 58: 131-135, 2004.
59. van den Berg MP, Merkus P, Romeijn SG, et al. Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: Studies in rats and comparison with a human study. Pharm Res 21: 799-802, 2004.
60. Van den Berg MP, Merkus P, Romeijn SG, et al. Hydroxocobalamin uptake into the cerebrospinal fluid after nasal and intravenous delivery in rats and humans. J Drug Target 11: 325-331, 2003.
61. Bagger MA, and Bechgaard E. The potential of nasal application for delivery to the central brain-a microdialysis study of fluorescein in rats. Eur J Pharm Sci 21: 235-242, 2004.
62. Bagger M, and Bechgaard E. A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. Int J Pharm 269: 311-322, 2004.
63. Yang Z, Huang Y, Gan G, and Sawchuk RJ. Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats. J Pharm Sci 94: 1577-1588, 2005.
64. Al-Ghananeem AM, Traboulsi AA, Dittert LW, and Hussain AA. Targeted brain delivery of 17 β-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech 3: E5, 2002.
65. Morrison EE, and Costanzo RM Morphology of olfactory epithelium in humans and other vertebrates. Microsc Res Tech 23: 49-61, 1992.
66. Bleier BS, Wang EW, Vandergrift WA, and Schlosser RJ. Mucocele rate after endoscopic skull base reconstruction using vascularized pedicled flaps. Am J Rhinol Allergy 25: 186-187, 2011.
67. Zhao HM, Liu XF, Mao XW, and Chen CF. Intranasal delivery of nerve growth factor to protect the central nervous system against acute cerebral infarction. Chin Med Sci J 19: 257-261, 2004.
68. Fisher AN, Illum L, Davis SS, and Schacht EH. Diiodo-L-tyrosine-labelled dextrans as molecular size markers of nasal absorption in the rat. J Pharm Pharmacol 44: 550-554, 1992.
69. Bernal-Sprekelsen M, Alobid I, Mullol J, et al. Closure of cerebrospinal fluid leaks prevents ascending bacterial meningitis. Rhinology 43: 277-281, 2005.
70. Bleier BS, Debnath I, Harvey RJ, and Schlosser RJ. Temporospatial quantification of fluorescein-labeled sinonasal irrigation delivery. Int Forum Allergy Rhinol 1: 361-365, 2011.